Another study demonstrated that anti‐ICAM‐1 antibody could be used for myeloma therapy and showed potential anti‐myeloma activity.[47] Our results also demonstrated that ICAM‐1 antibody or ICAM‐1 inhibition could inhibit the tumor metastasis in HCC after RFA. Here, ICAM1 is linked to hepatocellular carcinoma.